Jose Lucar, MD, is an infectious disease physician and associate professor of medicine in the Division of Infectious Diseases at the George Washington University (GW) School of Medicine and Health Sciences and the GW Medical Faculty Associates. After earning his medical degree from the Universidad Peruana Cayetano Heredia in Lima, Peru, he completed his internal medicine residency training at the Georgetown University Hospital – Washington Hospital Center program in 2014. Two years later, he completed his infectious diseases fellowship at GW. In 2016, he joined the Division of Infectious Diseases at the University of Mississippi Medical Center. There, he served as the medical director of the outpatient parenteral antimicrobial program until his return to GW in 2021. Dr. Lucar now serves as the medical director of GW Hospital's antimicrobial stewardship program. He is board certified in internal medicine and infectious diseases by the American Board of Internal Medicine, and in 2022 he was elected a Fellow of the Infectious Diseases Society of America. His clinical and research interests include mycobacterial infections, HIV treatment and prevention, infections in immunocompromised hosts, and emerging infectious diseases.
Education
Universidad Peruana Cayetano Heredia
Certifications
Infectious Diseases
Internal Medicine
Residencies
Georgetown University Hospital/Washington Hospital Center - Internal Medicine
Fellowships
George Washington University - Infectious Diseases
Clinical / Research Interests
Antimicrobial Stewardship
Mycobacterial infections
HIV treatment and prevention
Infections in immunocompromised hosts
Emerging infectious diseases
Biography
Clinical Trials
This is a phase 3 open label, multi-center, randomized, active-controlled non-inferiority trial that compares the safety and effectiveness of a 6-week regimen of daily rifapentine against the current standard of 12-16 weeks of rifamycin-based treatment for latent TB infection (LTBI).